Securities code: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) independent opinions of independent directors
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) independent director
Independent opinions on relevant matters of the company
As an independent director of Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) (hereinafter referred to as “the company”), we have carefully and carefully studied in accordance with the relevant provisions of the guiding opinions on the establishment of independent director system in listed companies, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 – standardized operation of listed companies on the main board and the articles of association of the company, The independent opinions on the relevant matters considered at the 17th meeting of the seventh board of directors of the company are as follows:
1、 Independent opinions on adjusting the list of incentive objects and the number of grants of the company’s restricted stock incentive plan in 2022
After verification, the board of directors of the company has fulfilled the necessary deliberation procedures on the adjustment of the list of incentive objects and the number of grants of the company’s restricted stock incentive plan in 2022, which is in line with the administrative measures for equity incentive of listed companies and the provisions on adjustment matters in the company’s incentive plan. This adjustment is within the scope of authorization given to the board of directors by the company’s first extraordinary general meeting in 2022, and the adjustment procedure is legal and compliant.
In conclusion, we unanimously agree that the company will adjust the list of incentive objects and the number of awards of the restricted stock incentive plan in 2022.
2、 Independent opinions on granting restricted shares to the incentive objects of the company’s restricted stock incentive plan in 2022
After verification, the granting date of the company’s restricted stock incentive plan in 2022 is March 1, 2022, which complies with the provisions on the granting date in the administrative measures for equity incentive of listed companies and the company’s restricted stock incentive plan in 2022 (Draft), At the same time, this grant also complies with the provisions of the company’s incentive plan on the conditions for the incentive object to be granted restricted shares. The subject qualification of the incentive object of the restricted stock incentive plan in 2022 is legal and effective. Neither the company nor the incentive object is allowed to grant restricted shares, and the grant conditions specified in this incentive plan have been met. The company does not provide loans, loan guarantees or any other forms of financial assistance to incentive objects. When the board of directors of the company considered the matters related to this grant, the review procedures and voting results were in line with the provisions of relevant laws, regulations, normative documents and the articles of association.
Securities code: Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) independent opinions of independent directors
In conclusion, we agree that the granting date of the company’s restricted stock incentive plan in 2022 is March 1, 2022, and 5780000 restricted shares are granted to 77 incentive objects.
Independent director: Deng Yanlin, Ruichao, Wu Qinggong
March 1, 2002
